Entrada Therapeutics (NASDAQ:TRDA) COO Sells $229,950.00 in Stock

Entrada Therapeutics, Inc. (NASDAQ:TRDA) COO Nathan Dowden sold 15,000 shares of the business’s stock in a transaction that occurred on Monday, May 4th. The stock was sold at an average price of $15.33, for a total transaction of $229,950.00. Following the completion of the transaction, the chief operating officer directly owned 198,588 shares of the company’s stock, valued at approximately $3,044,354.04. This represents a 7.02% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Entrada Therapeutics Stock Performance

Entrada Therapeutics stock opened at $16.03 on Thursday. Entrada Therapeutics, Inc. has a fifty-two week low of $4.93 and a fifty-two week high of $16.45. The stock has a market cap of $622.30 million, a P/E ratio of -4.63 and a beta of -0.09. The firm’s fifty day moving average price is $12.91 and its 200-day moving average price is $10.89.

Entrada Therapeutics (NASDAQ:TRDA) last announced its earnings results on Thursday, February 26th. The company reported ($0.94) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.32) by $0.38. Entrada Therapeutics had a negative net margin of 565.48% and a negative return on equity of 39.83%. The company had revenue of $1.30 million during the quarter, compared to analyst estimates of $7.41 million. On average, analysts predict that Entrada Therapeutics, Inc. will post -4.22 earnings per share for the current year.

Analysts Set New Price Targets

TRDA has been the topic of a number of research reports. Cantor Fitzgerald initiated coverage on Entrada Therapeutics in a report on Wednesday, April 1st. They set an “overweight” rating on the stock. Guggenheim upgraded shares of Entrada Therapeutics to a “strong-buy” rating in a research report on Wednesday, February 11th. HC Wainwright reissued a “buy” rating and set a $20.00 price target on shares of Entrada Therapeutics in a research note on Wednesday, February 18th. Wall Street Zen lowered shares of Entrada Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, March 28th. Finally, Oppenheimer upped their price objective on shares of Entrada Therapeutics from $21.00 to $23.00 and gave the company an “outperform” rating in a research note on Monday, April 6th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $19.00.

Institutional Investors Weigh In On Entrada Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of TRDA. Russell Investments Group Ltd. grew its position in Entrada Therapeutics by 72.7% during the 3rd quarter. Russell Investments Group Ltd. now owns 8,808 shares of the company’s stock worth $51,000 after acquiring an additional 3,707 shares during the last quarter. State of Wyoming increased its stake in Entrada Therapeutics by 130.9% in the 2nd quarter. State of Wyoming now owns 7,575 shares of the company’s stock worth $51,000 after purchasing an additional 4,295 shares during the period. AXQ Capital LP bought a new stake in Entrada Therapeutics in the third quarter valued at approximately $67,000. Occudo Quantitative Strategies LP bought a new stake in Entrada Therapeutics in the second quarter valued at approximately $68,000. Finally, Inscription Capital LLC purchased a new stake in shares of Entrada Therapeutics during the third quarter valued at approximately $69,000. Institutional investors own 86.39% of the company’s stock.

About Entrada Therapeutics

Entrada Therapeutics (NASDAQ: TRDA) is a clinical-stage biotechnology company focused on enabling the development of protein-based therapeutics that can cross cell membranes and engage intracellular targets. Using its proprietary cell-penetrating miniature protein (CPMP) platform and intracellular targeting of proteins (iTOP) delivery technology, Entrada aims to expand the range of diseases addressable by large-molecule drugs.

The company’s pipeline includes programs in rare and serious diseases where conventional biologics have limited intracellular activity.